MENLO PARK, Calif., July 25 /PRNewswire-FirstCall/ -- XTENT, Inc. announced that it will report its financial results for the second quarter 2007 after market close on Tuesday, August 7, 2007. The company will hold a conference call the same day at 2 p.m. Pacific Time (5 p.m. Eastern Time). The call will be hosted by Gregory D. Casciaro, XTENT's President and Chief Executive Officer, and Tim Kahlenberg, Chief Financial Officer.
The teleconference can be accessed via the investor relations section of the company's website at http://investor.xtentinc.com/events.cfm or by calling 800-776-0816 (domestic), 913-981-5556 (international). Please dial in or access the website 5 to 10 minutes prior to the beginning of the call.
An online archive of the webcast will be available for a minimum of three months by accessing the investor relations portion of the company's website at http://investor.xtentinc.com.
As a result of the timing of the earnings release, the lock-up agreements entered into in conjunction with the company's initial public offering will be extended until 18 days after XTENT's earnings release, or through Friday, August 24, 2007. The first sales of previously restricted shares may take place on Monday, August 27. The lock-up period was due to expire on July 30, but the lock-up agreements provide for an extension, depending on the timing of XTENT's quarterly earnings press release.
This extension affects approximately 18.2 million shares of common stock. Upon expiration of the lock-up period, these shares will be eligible for resale subject to any resale restrictions of the federal securities laws, including, in some instances, the limitations of Rules 144 and 701 under the Securities Act of 1933, as amended.
About XTENT
XTENT, Inc. is a medical device company focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). CAD is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device. Note: XTENT(R) Custom NX(R) DES Systems have not been approved for sale by any regulatory authority.
XTENT, Inc.CONTACT: Investor Relations, Tim Kahlenberg, Chief Financial Officer ofXTENT, Inc., +1-650-475-9400, tkahlenberg@xtentinc.com; or Media Relations,Danielle Bertrand, +1-415-946-1056, dbertrand@weisscommpartners.com, forXTENT, Inc.
Web site: http://investor.xtentinc.com/
